SE520392C2 - Specifika peptider för behandling av diabetes mellitus - Google Patents

Specifika peptider för behandling av diabetes mellitus

Info

Publication number
SE520392C2
SE520392C2 SE9603533A SE9603533A SE520392C2 SE 520392 C2 SE520392 C2 SE 520392C2 SE 9603533 A SE9603533 A SE 9603533A SE 9603533 A SE9603533 A SE 9603533A SE 520392 C2 SE520392 C2 SE 520392C2
Authority
SE
Sweden
Prior art keywords
peptide
insulin
mixture
amino acid
acid sequence
Prior art date
Application number
SE9603533A
Other languages
English (en)
Swedish (sv)
Other versions
SE9603533L (sv
SE9603533D0 (sv
Inventor
John Wahren
Bo-Lennart Johansson
Hans Joernvall
Original Assignee
Creative Peptides Sweden Ab C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Peptides Sweden Ab C filed Critical Creative Peptides Sweden Ab C
Priority to SE9603533A priority Critical patent/SE520392C2/sv
Publication of SE9603533D0 publication Critical patent/SE9603533D0/xx
Priority to ES97942119T priority patent/ES2278394T3/es
Priority to PL97332494A priority patent/PL332494A1/xx
Priority to AU43915/97A priority patent/AU741901B2/en
Priority to AT97942119T priority patent/ATE347562T1/de
Priority to HU0000432A priority patent/HUP0000432A3/hu
Priority to BR9711573-8A priority patent/BR9711573A/pt
Priority to NZ335231A priority patent/NZ335231A/xx
Priority to DK97942119T priority patent/DK0938503T3/da
Priority to RU99108434/14A priority patent/RU2206336C2/ru
Priority to JP10515410A priority patent/JP2001500893A/ja
Priority to PCT/GB1997/002627 priority patent/WO1998013384A1/en
Priority to EP97942119A priority patent/EP0938503B1/de
Priority to SK394-99A priority patent/SK39499A3/sk
Priority to US09/269,439 priority patent/US6610649B2/en
Priority to TR1999/00694T priority patent/TR199900694T2/xx
Priority to CZ991085A priority patent/CZ108599A3/cs
Priority to DE69737065T priority patent/DE69737065T2/de
Priority to CA002266416A priority patent/CA2266416C/en
Priority to KR1019990702585A priority patent/KR20000048643A/ko
Priority to IL12914397A priority patent/IL129143A0/xx
Publication of SE9603533L publication Critical patent/SE9603533L/
Priority to IS5008A priority patent/IS5008A/is
Priority to NO991483A priority patent/NO991483L/no
Priority to BG103362A priority patent/BG103362A/xx
Publication of SE520392C2 publication Critical patent/SE520392C2/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
SE9603533A 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus SE520392C2 (sv)

Priority Applications (24)

Application Number Priority Date Filing Date Title
SE9603533A SE520392C2 (sv) 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus
IL12914397A IL129143A0 (en) 1996-09-27 1997-09-26 Insulin c-peptides
EP97942119A EP0938503B1 (de) 1996-09-27 1997-09-26 Insulin c-peptide
US09/269,439 US6610649B2 (en) 1996-09-27 1997-09-26 Insulin C-peptides
AU43915/97A AU741901B2 (en) 1996-09-27 1997-09-26 Insulin C-peptides
AT97942119T ATE347562T1 (de) 1996-09-27 1997-09-26 Insulin c-peptide
HU0000432A HUP0000432A3 (en) 1996-09-27 1997-09-26 Insulin c-peptides
BR9711573-8A BR9711573A (pt) 1996-09-27 1997-09-26 Pepetìdeos c da insulina.
NZ335231A NZ335231A (en) 1996-09-27 1997-09-26 Human fragments of insulin C-peptides of the sequence ELGGGPGAG or EGSLQ that have Na/K ATPase stimulating activity
DK97942119T DK0938503T3 (da) 1996-09-27 1997-09-26 Insulin C-peptider
RU99108434/14A RU2206336C2 (ru) 1996-09-27 1997-09-26 Фрагмент с-пептида человеческого проинсулина
JP10515410A JP2001500893A (ja) 1996-09-27 1997-09-26 インスリンc―ペプチド
PCT/GB1997/002627 WO1998013384A1 (en) 1996-09-27 1997-09-26 Insulin c-peptides
ES97942119T ES2278394T3 (es) 1996-09-27 1997-09-26 Peptidos c de la insulina.
SK394-99A SK39499A3 (en) 1996-09-27 1997-09-26 Peptide, biomimetic organic compound thereof, pharmaceutical composition containing it and its use
PL97332494A PL332494A1 (en) 1996-09-27 1997-09-26 Peptides of c insulin
TR1999/00694T TR199900694T2 (xx) 1996-09-27 1997-09-26 �nsulin C-peptitleri.
CZ991085A CZ108599A3 (cs) 1996-09-27 1997-09-26 Peptid, který je fragmentem C-peptidu lidského inzulinu
DE69737065T DE69737065T2 (de) 1996-09-27 1997-09-26 Insulin c-peptide
CA002266416A CA2266416C (en) 1996-09-27 1997-09-26 Insulin c-peptides
KR1019990702585A KR20000048643A (ko) 1996-09-27 1997-09-26 인슐린 c-펩티드
IS5008A IS5008A (is) 1996-09-27 1999-03-23 C-peptíð insúlíns
NO991483A NO991483L (no) 1996-09-27 1999-03-26 Insulin C-peptider
BG103362A BG103362A (en) 1996-09-27 1999-04-27 Insulin c-peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603533A SE520392C2 (sv) 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus

Publications (3)

Publication Number Publication Date
SE9603533D0 SE9603533D0 (sv) 1996-09-27
SE9603533L SE9603533L (sv) 1998-03-28
SE520392C2 true SE520392C2 (sv) 2003-07-01

Family

ID=20404052

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9603533A SE520392C2 (sv) 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus

Country Status (24)

Country Link
US (1) US6610649B2 (de)
EP (1) EP0938503B1 (de)
JP (1) JP2001500893A (de)
KR (1) KR20000048643A (de)
AT (1) ATE347562T1 (de)
AU (1) AU741901B2 (de)
BG (1) BG103362A (de)
BR (1) BR9711573A (de)
CA (1) CA2266416C (de)
CZ (1) CZ108599A3 (de)
DE (1) DE69737065T2 (de)
DK (1) DK0938503T3 (de)
ES (1) ES2278394T3 (de)
HU (1) HUP0000432A3 (de)
IL (1) IL129143A0 (de)
IS (1) IS5008A (de)
NO (1) NO991483L (de)
NZ (1) NZ335231A (de)
PL (1) PL332494A1 (de)
RU (1) RU2206336C2 (de)
SE (1) SE520392C2 (de)
SK (1) SK39499A3 (de)
TR (1) TR199900694T2 (de)
WO (1) WO1998013384A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022342D0 (en) 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
DE10055857A1 (de) * 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
JP5452843B2 (ja) * 2003-01-06 2014-03-26 エミスフィアー テクノロジーズ インコーポレイテッド 夜間の経口インスリン治療
US20050026826A1 (en) * 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
US7557081B2 (en) * 2004-05-27 2009-07-07 Essential Skincare, Llc Alpha-1-acid glycoprotein for the treatment of diabetes
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
GB0601950D0 (en) * 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
EP2054437A2 (de) * 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin-fusionsproteine
US20100292132A1 (en) * 2007-09-11 2010-11-18 Dorian Bevec Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
GB0723250D0 (en) * 2007-11-28 2008-01-09 Univ Leeds Compositions and methods for reducing macrovascular complications in diabetic patients
US8680263B2 (en) 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2334338A2 (de) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymerkonjugate von c-peptiden
US8410049B2 (en) * 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
CN103119055A (zh) 2010-05-17 2013-05-22 塞比克斯公司 聚乙二醇化c肽
CA2827029C (en) 2011-02-11 2019-07-02 The Regents Of The University Of Michigan Tripeptide compositions and methods
CN104220086A (zh) 2011-11-17 2014-12-17 塞比克斯股份公司 Peg化的c-肽
RU2522897C1 (ru) * 2013-04-16 2014-07-20 Закрытое акционерное общество "ФАРМ-ХОЛДИНГ" Твердая кишечнорастворимая лекарственная форма с-пептида проинсулина для перорального применения (варианты) и способ ее получения (варианты)
KR101676542B1 (ko) * 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도
CN104888201B (zh) * 2015-06-29 2018-04-27 齐锦生 用于防治糖尿病及其慢性并发症的肽类药物
EP3570875B1 (de) 2017-02-06 2022-07-06 Biotempt B.V. Peptidmodulatoren der wechselwirkung zwischen menschlichem c-peptid und menschlichem elastinrezeptor zur therapeutischen verwendung

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU166913B (de) * 1972-05-15 1975-06-28
JPS5210872B2 (de) * 1973-07-14 1977-03-26
JPS55105653A (en) * 1978-10-02 1980-08-13 Shionogi & Co Ltd Tyrosyl c-peptides
CA1176158A (en) 1981-08-27 1984-10-16 Ronald E. Chance Pharmaceutical formulations comprising human insulin and human c-peptide
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4581165A (en) * 1984-06-14 1986-04-08 Eli Lilly And Company Anti-diabetic compounds
US5104854A (en) 1989-02-01 1992-04-14 Washington University Antiviral peptides
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
US5364757A (en) 1990-05-21 1994-11-15 Administrators Of The Tulane Educational Fund Methods of supporting a diagnosis of systemic lupus erythematosus
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH05268982A (ja) 1992-03-27 1993-10-19 Hoechst Japan Ltd 骨形成作用を有する新規な蛋白質およびその製造法
DE69327239T2 (de) 1992-04-13 2000-05-11 Oklahoma Med Res Found Methoden and reagentien zur diagnose von autoantikörpern
WO1994025071A1 (en) 1993-05-05 1994-11-10 Keith Rose Polyoxime compounds and their preparation
AT400723B (de) 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante alternaria alternata allergene
WO1996001846A1 (en) 1994-07-08 1996-01-25 Trustees Of Dartmouth College Proinsulin peptide compounds for detecting and treating type i diabetes
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509164D0 (en) 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
AU728186B2 (en) 1996-03-15 2001-01-04 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US6150500A (en) 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase

Also Published As

Publication number Publication date
IS5008A (is) 1999-03-23
DE69737065T2 (de) 2007-06-28
RU2206336C2 (ru) 2003-06-20
IL129143A0 (en) 2000-02-17
JP2001500893A (ja) 2001-01-23
CZ108599A3 (cs) 1999-08-11
BR9711573A (pt) 2000-01-18
SE9603533L (sv) 1998-03-28
CA2266416A1 (en) 1998-04-02
WO1998013384A1 (en) 1998-04-02
KR20000048643A (ko) 2000-07-25
TR199900694T2 (xx) 1999-06-21
NO991483D0 (no) 1999-03-26
AU741901B2 (en) 2001-12-13
BG103362A (en) 2000-05-31
CA2266416C (en) 2008-04-29
DE69737065D1 (en) 2007-01-18
US20020107175A1 (en) 2002-08-08
AU4391597A (en) 1998-04-17
PL332494A1 (en) 1999-09-13
HUP0000432A3 (en) 2000-10-30
SE9603533D0 (sv) 1996-09-27
ATE347562T1 (de) 2006-12-15
US6610649B2 (en) 2003-08-26
NO991483L (no) 1999-05-18
DK0938503T3 (da) 2007-04-10
ES2278394T3 (es) 2007-08-01
NZ335231A (en) 2000-11-24
SK39499A3 (en) 1999-10-08
HUP0000432A2 (hu) 2000-08-28
EP0938503B1 (de) 2006-12-06
EP0938503A1 (de) 1999-09-01

Similar Documents

Publication Publication Date Title
SE520392C2 (sv) Specifika peptider för behandling av diabetes mellitus
ES2402522T3 (es) Composiciones y procedimientos para aumentar la sensibilidad a la insulina
ES2325773T3 (es) Tratamiento de la obesidad y los trastornos relacionados.
ES2307619T3 (es) Tratamiento del sindrome coronario agudo con glp-1.
ES2383796T3 (es) Composiciones farmacéuticas que comprenden grelina no acilada para su utilización en el tratamiento de la resistencia a la insulina
US5939387A (en) Method of treating insulin resistance
ZA200306332B (en) Methods of treating diabetes mellitus
JP6438944B2 (ja) インスリングラルギン/リキシセナチド固定比率製剤
JP2000511561A (ja) 肥満症の処置のためのcntf(毛様体神経成長因子)受容体アクティベーターの使用
ES2753976T3 (es) Prevención de diabetes de tipo 2
BRPI0719821B1 (pt) composição estável na armazenagem apropriada para administração a pacientes
WO2008040260A1 (es) Uso del factor de crecimiento epidérmico para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
BR112020013733A2 (pt) composições e métodos para tratar doenças metabólicas
Factor Dopamine agonists
Ladenheim et al. Caudal hindbrain neuromedin B-preferring receptors participate in the control of food intake
CA2568305C (en) Insulin-independent, bone morphogenetic protein (bmp)-mediated uptake of blood glucose by peripheral cells and tissues
AU2020203126A1 (en) Pharmaceutical solution comprising dopamine for use in treating Parkinson's disease
ES2319427T3 (es) Aplicaciones terapeuticas del peptido c.
CA2517896A1 (en) Use of thyroid-stimulating hormone to induce lipolysis
AU2017206624A1 (en) Pharmaceutical formulations for the treatment of diabetes
Ogren et al. Galanin: regulation of cholinergic function and behaviour
WO2002038152A1 (es) Combinacion de aminas y compuestos de vanadio (iv)/(v) para el tratamiento y/o la prevencion de la diabetes mellitus
KR20110052990A (ko) 인슐린 글라르긴 및 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
CN109475552B (zh) 用于食欲控制和体重管理的方法和组合物
TWI837615B (zh) 含腸促胰島素(incretin)類似物之組合物及其用途

Legal Events

Date Code Title Description
NUG Patent has lapsed